Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Bipolar Disorder, Major Depressive Disorder
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Low Risk Acute Coronary Syndrome
Interventions: Stress Test, No Stress Test; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cardiovascular Risk Factor
Interventions: Multicomponent Virtual Lifestyle Intervention; Behavioral
Lead sponsor: Truemedicine Inc; Other
Eligibility: 30 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1 Infection
Interventions: Niacin, Aspirin, Fenofibrate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and atorvastatin tablets, colesevelam HCl placebo tablets and atorvastatin tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 13
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 10 more

Conditions: Type 2 Diabetes
Interventions: Statin, PCSK9 inhibitor, Ezetimibe 10mg; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Disease, Hyperlipidemia
Interventions: Avocado Diet, Lower-Fat Diet, Moderate Fat Diet; Other
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: bempedoic acid 180mg, placebo, evolocumab; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Hypercholesterolemia
Interventions: alirocumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Type 2 Diabetes
Interventions: Intensive lifestyle intervention, Diabetes support and education; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 45 Years to 74 Years
Enrollment: 4,108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more

Conditions: Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions: Valsartan and simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions: Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Microbiome
Interventions: strawberry powder, placebo powder; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabete Type 2, Obesity & Overweight, Nutritional Intervention, Food Insecurity
Interventions: Meal kits, No-prep meals, Culinary nutrition classes, Text messages; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Dietary supplement for weight loss, Education and counseling for weight loss; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Quercetin, Lipid Metabolism, Aging
Interventions: Quercetin Phytosome; Dietary Supplement
Lead sponsor: Thorne HealthTech, Inc; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Summerville, South Carolina

Conditions: Estrogen Deficiency
Interventions: Blood test, Blood test, Ultrasound of neck arteries, Saliva test; Procedure · Genetic
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Up to 55 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pregnancy Related
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypercholesterolemia, Aches, Cramps, Weakness
Interventions: Creatine; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Wooster, Ohio

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: lerodalcibep 300 mg Monthly SC; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: University of Oxford; Other
Eligibility: 40 Years and older
Enrollment: 16,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2049
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study Using Pregnenolone to Treat Bipolar Depression

Impact of LDL-cholesterol Lowering on Platelet Activation

Low Risk Acute Coronary Syndrome

Virtual Lifestyle Intervention for Weight Management and Cardiovascular Heal

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Gene x Behavior Interaction in the Look AHEAD Study

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Effect of Strawberry Consumption on the Microbiome

Nutrition Intervention Optimization to Better Utilize Resources and Support Health

Risk Reduction for Alzheimer's Disease

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Effects of Quercetin on Metabolic Health

Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women

Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease